| Not Yet Recruiting | Characterization of Autoreactive b Lymphocytes in Autoimmune Diseases and Immune Deficiencies NCT07251179 | University Hospital, Strasbourg, France | — |
| Not Yet Recruiting | Clinical Study of BCT301 Cell Injection Therapy for Refractory Autoimmune Diseases NCT07301164 | Peking University Third Hospital | EARLY_Phase 1 |
| Not Yet Recruiting | EACVI Study on Multimodality Cardiovascular Imaging of Inflammatory Cardiovascular Diseases NCT07077304 | Assistance Publique - Hôpitaux de Paris | — |
| Recruiting | (68)Ga-FAPI PET/CT in Patients With ANCA-associated Vasculitis NCT07151521 | Ruijin Hospital | — |
| Recruiting | A Study of Anti-CD19/BCMA Universal CAR-T Cell Therapy RD06-05 in Patients With Autoimmune Diseases. NCT07203404 | Nanjing Bioheng Biotech Co., Ltd. | EARLY_Phase 1 |
| Not Yet Recruiting | Clinical Study on the Targeted CD19 Universal CAR-T Cell Injection (RD06-04) for the Treatment of IIM and AAV NCT06986018 | Peking University People's Hospital | EARLY_Phase 1 |
| Not Yet Recruiting | Epithelial Dysmetabolism and Renal Fibrosis in ANCA Vasculitis NCT07010250 | Assistance Publique - Hôpitaux de Paris | — |
| Not Yet Recruiting | UCAR T-cell Therapy Targeting CD19/ BCMA in Patients With Relapse/ Refractory Autoimmune Diseases NCT06978738 | Changzhou No.2 People's Hospital | Phase 1 |
| Recruiting | BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases NCT06794008 | Peking University People's Hospital | Phase 2 |
| Recruiting | Anti-CD19 CAR T-Cell Therapy in Refractory Systemic Autoimmune Diseases NCT06685042 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Phase 1 / Phase 2 |
| Recruiting | Clinical Study on Targeted CD19 or CD19-BCMA CAR-T Therapy for Autoimmune Diseases NCT06548607 | Nanjing Bioheng Biotech Co., Ltd. | EARLY_Phase 1 |
| Suspended | Clinical Study on Targeted CD19CAR-T Therapy for Autoimmune Diseases NCT06549296 | Nanjing Bioheng Biotech Co., Ltd. | EARLY_Phase 1 |
| Withdrawn | A Study of RD06-04 in Patients With Active Autoimmune Diseases NCT06548620 | Nanjing Bioheng Biotech Co., Ltd. | EARLY_Phase 1 |
| Active Not Recruiting | CARTIMMUNE: Study of Patients With Autoimmune Diseases Receiving KYV-101 NCT06152172 | David Porter | Phase 1 |
| Recruiting | Study of Therapeutic Efficacy of Anti-CD19 CAR-T Cells in Children With Refractory Refractory AAV NCT06508346 | The Children's Hospital of Zhejiang University School of Medicine | — |
| Not Yet Recruiting | The Safety and Efficacy of Anti-CD19 CAR-T Cells in Patients With Relapsed/Refractory Autoimmune Diseases NCT06420154 | First Affiliated Hospital of Wenzhou Medical University | EARLY_Phase 1 |
| Recruiting | Anti-CD19-CD3E-CAR-T Cells in Relapsed/Refractory Autoimmune Disease NCT06373081 | Shanghai Changzheng Hospital | N/A |
| Recruiting | The BCMA/CD19 Dual Targeted CAR-T Cell in Participants With Autoimmune Kidney Diseases NCT06285279 | Nanjing University School of Medicine | Phase 1 |
| Recruiting | Refractory ANCA Associated Vasculitis and Lupus Nephritis Treated With BCMA-targeting CAR-T Cells NCT06277427 | Lingli Dong | N/A |
| Recruiting | Neutrophil Extracellular Traps in Different Forms of Systemic Sclerosis NCT06462768 | CHU de Reims | — |
| Recruiting | Early-access Avacopan in Real-world ANCA-associated Vasculitis NCT06794827 | Leiden University Medical Center | — |
| Recruiting | A Trial to Evaluate the Efficacy of Pioglitazone to Promote Renal Tolerance in ANCA-associated Vasculitis - RE NCT05946564 | Assistance Publique - Hôpitaux de Paris | Phase 3 |
| Recruiting | Avacostar - (PASS) NCT05897684 | Vifor Fresenius Medical Care Renal Pharma | — |
| Terminated | PR3-AAV Resilient Remission or PRRR NCT05376319 | Mayo Clinic | Phase 2 |
| Recruiting | Efficacy and Safety for Rituximab Combined With Telitacicept in the Treatment of ANCA-associated Vasculitis (T NCT05962840 | Chinese SLE Treatment And Research Group | Phase 4 |
| Recruiting | Efficacy and Safety for Telitacicept in the Remission Maintenance Treatment of ANCA-associated Vasculitis (TTC NCT05965284 | Chinese SLE Treatment And Research Group | Phase 4 |
| Active Not Recruiting | ETA and AT1 Antagonism in ANCA-vasculitis (SPARVASC) NCT05630612 | University of Edinburgh | Phase 2 |
| Recruiting | Biocollection of Patients With ANCA Associated Vasculitis NCT05364892 | University Hospital, Brest | N/A |
| Unknown | Occupational and Environmental Origins of ANCA Vasculitis: Contribution of Data From the National Network for NCT05416723 | University Hospital, Brest | — |
| Active Not Recruiting | Subclinical Cytomegalovirus Reactivation in Acute ANCA-associated Vasculitis NCT04916704 | University Hospital Birmingham NHS Foundation Trust | — |
| Recruiting | Multicenter Cohort Study of AAV in Hunan of China NCT05315141 | Xiangya Hospital of Central South University | — |
| Completed | Efficacy and Safety of Substitution of Glucocorticoid for BDB-001 Injection in Patients With Anti-neutrophil C NCT05197842 | Staidson (Beijing) Biopharmaceuticals Co., Ltd | Phase 1 / Phase 2 |
| Unknown | Pediatric ANCA Associated-vasculitis NCT05383573 | University Hospital, Strasbourg, France | — |
| Unknown | the Application of Diffusion Tensor Imaging in the Evaluation of Peripheral Neuropathy in ANCA Associated Vasc NCT04923074 | Second Affiliated Hospital, School of Medicine, Zhejiang University | — |
| Unknown | Comparison of the Efficacy of Leflunomide and Azathioprine for the Maintenance Therapy of ANCA Associated Vasc NCT04737343 | Chinese SLE Treatment And Research Group | N/A |
| Completed | Biosimilars of Rituximab in ANCA-associated Vasculitis Compared to the Originator NCT05716334 | McGill University Health Centre/Research Institute of the McGill University Health Centre | — |
| Completed | Patients With Co-occurrence of ANCA Vasculitis and Sjögren Syndrome NCT04895878 | University Hospital, Montpellier | — |
| Recruiting | PRediction of DIverse Glucocorticoids ToxIcity OUtcomeS NCT04664465 | University Hospital, Brest | — |
| Unknown | Hydroxychloroquine in ANCA Vasculitis Evaluation NCT04316494 | Guy's and St Thomas' NHS Foundation Trust | Phase 4 |
| Completed | PRagmatic Analysis of Vitamin D in ANCA-Associated Vasculitis NCT04280601 | Christian Pagnoux | N/A |
| Completed | Effect of Tofacitinib in Treating ANCA-associated Vasculitis NCT04973033 | Shanghai Zhongshan Hospital | N/A |
| Terminated | Tailoring Maintenance Therapy to Cluster of Differentiation 5 Positive (CD5+) Regulatory B Cell Recovery in AN NCT03906227 | University of North Carolina, Chapel Hill | N/A |
| Unknown | Exploring Durable Remission With Rituximab in Antineutrophil Cytoplasmic Antibody(ANCA)-Associated Vasculitis NCT03942887 | Leiden University Medical Center | Phase 3 |
| Unknown | Rituximab and Belimumab Combination Therapy in PR3 Vasculitis NCT03967925 | Rachel Jones | Phase 2 |
| Completed | Soluble CD95 Ligand Role in the Pathophysiology of Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vascu NCT03698071 | University Hospital, Bordeaux | N/A |
| Completed | MICRO-RNAs OF NEUTROPHILS IN RENAL ANTINEUTROPHIL CYTOPLASMIS ANTIBODY (ANCA) -ASSOCIATED VASCULITIS NCT02954705 | Nantes University Hospital | — |
| Completed | A Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis NCT02994927 | Amgen | Phase 3 |
| Completed | Residual Anti-pneumococcal Immunity After Pneumococcal Immunization in ANCA-associated Vasculitis NCT02463539 | Assistance Publique - Hôpitaux de Paris | — |
| Unknown | Immunogenicity of a Combined Anti-pneumococcal Vaccine Schedule in Patients With ANCA-associated Vasculitis NCT02463578 | Assistance Publique - Hôpitaux de Paris | — |
| Completed | Abatacept for the Treatment of Relapsing, Non-Severe, Granulomatosis With Polyangiitis (Wegener's) NCT02108860 | University of South Florida | Phase 3 |
| Completed | Clinical Trial to Evaluate Safety and Efficacy of CCX168 in ANCA-Associated Vasculitis NCT02222155 | Amgen | Phase 2 |
| Recruiting | Studies of the Natural History, Pathogenesis, and Outcome of Idiopathic Systemic Vasculitis NCT02257866 | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | — |
| Unknown | Observation Study of Clinical Manifestation and Outcome in Chinese Patients With Pulmonary Vasculitis NCT02126098 | Peking Union Medical College Hospital | — |
| Terminated | Defining Immune Tolerance in ANCA-associated Vasculitis (AAV) NCT01934504 | National Institute of Allergy and Infectious Diseases (NIAID) | — |
| Unknown | CMV Modulation of the Immune System in ANCA-associated Vasculitis NCT01633476 | Professor Lorraine Harper | Phase 2 |
| Terminated | Abatacept in ANCA Associated Vasculitis NCT00482066 | Imperial College London | Phase 2 |
| Completed | Pilot Study of Rituximab Therapy for Systemic Lupus Erythematosus (SLE) and Vasculitis NCT00293072 | Cambridge University Hospitals NHS Foundation Trust | Phase 2 |